CN108366994B - 新型Jak1选择性抑制剂及其用途 - Google Patents
新型Jak1选择性抑制剂及其用途 Download PDFInfo
- Publication number
- CN108366994B CN108366994B CN201780004442.5A CN201780004442A CN108366994B CN 108366994 B CN108366994 B CN 108366994B CN 201780004442 A CN201780004442 A CN 201780004442A CN 108366994 B CN108366994 B CN 108366994B
- Authority
- CN
- China
- Prior art keywords
- compound
- disease
- equiv
- imidazo
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Catalysts (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110514751.5A CN113214278B (zh) | 2016-10-03 | 2017-09-30 | 新型Jak1选择性抑制剂及其用途 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662403660P | 2016-10-03 | 2016-10-03 | |
| US62/403,660 | 2016-10-03 | ||
| PCT/US2017/054668 WO2018067422A1 (en) | 2016-10-03 | 2017-09-30 | Novel jak1 selective inhibitors and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110514751.5A Division CN113214278B (zh) | 2016-10-03 | 2017-09-30 | 新型Jak1选择性抑制剂及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108366994A CN108366994A (zh) | 2018-08-03 |
| CN108366994B true CN108366994B (zh) | 2021-10-01 |
Family
ID=61831161
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780004442.5A Active CN108366994B (zh) | 2016-10-03 | 2017-09-30 | 新型Jak1选择性抑制剂及其用途 |
| CN202110514751.5A Active CN113214278B (zh) | 2016-10-03 | 2017-09-30 | 新型Jak1选择性抑制剂及其用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110514751.5A Active CN113214278B (zh) | 2016-10-03 | 2017-09-30 | 新型Jak1选择性抑制剂及其用途 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10738060B2 (enExample) |
| EP (1) | EP3509591B1 (enExample) |
| JP (1) | JP7089141B2 (enExample) |
| KR (1) | KR102399848B1 (enExample) |
| CN (2) | CN108366994B (enExample) |
| AU (3) | AU2017339417C1 (enExample) |
| DK (1) | DK3509591T3 (enExample) |
| EA (1) | EA201990523A1 (enExample) |
| ES (1) | ES2901216T3 (enExample) |
| HK (1) | HK1253040A1 (enExample) |
| HR (1) | HRP20211965T1 (enExample) |
| HU (1) | HUE058120T2 (enExample) |
| IL (3) | IL265358B (enExample) |
| MX (1) | MX390005B (enExample) |
| NZ (1) | NZ751284A (enExample) |
| PL (1) | PL3509591T3 (enExample) |
| PT (1) | PT3509591T (enExample) |
| RS (1) | RS62695B1 (enExample) |
| WO (1) | WO2018067422A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE058120T2 (hu) | 2016-10-03 | 2022-07-28 | Highlightll Pharmaceutical Hainan Co Ltd | Új JAK1-szelektív inhibitorok és alkalmazásuk |
| PL3568396T3 (pl) * | 2017-01-11 | 2021-05-31 | Leo Pharma A/S | Nowe pochodne aminoimidazopirydyny jako inhibitory kinaz janusowych i ich zastosowanie farmaceutyczne |
| CN113490484B (zh) | 2018-10-31 | 2024-08-23 | 因赛特公司 | 治疗血液疾病的组合疗法 |
| JP2022524997A (ja) | 2019-03-05 | 2022-05-11 | インサイト・コーポレイション | 慢性肺同種移植片機能不全の治療のためのｊａｋ１経路阻害剤 |
| US11624751B2 (en) | 2019-03-19 | 2023-04-11 | Incyte Corporation | Biomarkers for vitiligo |
| EP3981398A4 (en) * | 2019-06-06 | 2023-03-15 | Hangzhou Highlightll Pharmaceutical Co., Ltd. | METHOD FOR SYNTHESIS OF A FUROIMIDAZOPYRIDINE COMPOUND, POLYMORPHOUS SUBSTANCE AND POLYMORPHOUS SUBSTANCE OF A SALT |
| KR102785014B1 (ko) * | 2019-06-06 | 2025-03-20 | 항저우 하이라이트엘엘 파마슈티컬 씨오., 엘티디. | 푸로이미다조피리딘 화합물의 합성 방법, 푸로이미다조피리딘 화합물의 결정 형태, 및 그의 염의 결정 형태 |
| BR112022023550A2 (pt) | 2020-05-19 | 2023-01-03 | Bayer Cropscience Ag | (tio)amidas azabicíclicas como compostos fungicidas |
| WO2021249995A1 (en) | 2020-06-10 | 2021-12-16 | Bayer Aktiengesellschaft | Azabicyclyl-substituted heterocycles as fungicides |
| US20240307396A1 (en) * | 2021-06-07 | 2024-09-19 | The Regents Of The University Of California | Compositions and methods for treating celiac disease |
| IL313097A (en) * | 2021-09-13 | 2024-07-01 | Hangzhou Highlightll Pharmaceutical Co Ltd | Methods of treating cns disorders |
| CN114213424B (zh) * | 2021-12-30 | 2023-05-26 | 杭州高光制药有限公司 | 一种呋喃[3，2-b]并吡啶衍生物的合成方法 |
| WO2025224600A1 (en) * | 2024-04-21 | 2025-10-30 | Biohaven Therapeutics Ltd. | Treatment of alpha-synucleinopathies and neuroprotection |
| WO2025248468A1 (en) | 2024-05-28 | 2025-12-04 | Biohaven Therapeutics Ltd. | Use of tyk2/jak1 inhibitors to treat amyloid-related imaging abnormalities (aria) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014071031A1 (en) * | 2012-11-01 | 2014-05-08 | Incyte Corporation | Tricyclic fused thiophene derivatives as jak inhibitors |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4369172A (en) | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
| ATE66143T1 (de) | 1985-01-11 | 1991-08-15 | Abbott Lab | Feste zubereitung mit langsamer freisetzung. |
| JP2773959B2 (ja) | 1990-07-10 | 1998-07-09 | 信越化学工業株式会社 | 大腸内放出性固形製剤 |
| UA73092C2 (uk) | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
| US6638534B1 (en) | 1998-07-28 | 2003-10-28 | Tanabe Seiyaku Co., Ltd. | Preparation capable of releasing drug at target site in intestine |
| JP2000119271A (ja) | 1998-08-12 | 2000-04-25 | Hokuriku Seiyaku Co Ltd | １ｈ―イミダゾピリジン誘導体 |
| US6461631B1 (en) | 1999-11-16 | 2002-10-08 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| US6800663B2 (en) | 2002-10-18 | 2004-10-05 | Alkermes Controlled Therapeutics Inc. Ii, | Crosslinked hydrogel copolymers |
| WO2005085227A1 (en) | 2004-03-02 | 2005-09-15 | Smithkline Beecham Corporation | Inhibitors of akt activity |
| CN101277965A (zh) * | 2005-08-04 | 2008-10-01 | 西特里斯药业公司 | 作为SIRTUIN调节化合物的咪唑并[2,1-b]噻唑衍生物 |
| CN102741253A (zh) * | 2009-09-29 | 2012-10-17 | 艾科睿控股公司 | PI3K(δ)选择性抑制剂 |
| WO2012022045A1 (en) * | 2010-08-20 | 2012-02-23 | Hutchison Medipharma Limited | Pyrrolopyrimidine compounds and uses thereof |
| AU2011311867A1 (en) | 2010-10-08 | 2013-04-18 | Abbvie Inc. | Furo(3,2-d)pyrimidine compounds |
| WO2013007768A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors |
| BR112014002472A2 (pt) | 2011-08-12 | 2017-04-11 | Nissan Chemical Ind Ltd | "compostos heterocíclicos tricíclicos, seu uso, agente terapêutico para reumatismo articular e medicamento" |
| AU2014339897A1 (en) | 2013-10-24 | 2016-04-21 | Abbvie Inc. | JAK1 selective inhibitor and uses thereof |
| MX2016014192A (es) | 2014-04-30 | 2017-05-01 | Incyte Corp | Procesos para preparar un inhibidor de cinasas de janus 1 (jak1) y nuevas formas de este. |
| WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| HUE058120T2 (hu) | 2016-10-03 | 2022-07-28 | Highlightll Pharmaceutical Hainan Co Ltd | Új JAK1-szelektív inhibitorok és alkalmazásuk |
-
2017
- 2017-09-30 HU HUE17858944A patent/HUE058120T2/hu unknown
- 2017-09-30 HK HK18112420.5A patent/HK1253040A1/zh unknown
- 2017-09-30 CN CN201780004442.5A patent/CN108366994B/zh active Active
- 2017-09-30 US US16/333,994 patent/US10738060B2/en not_active Ceased
- 2017-09-30 AU AU2017339417A patent/AU2017339417C1/en active Active
- 2017-09-30 JP JP2019517991A patent/JP7089141B2/ja active Active
- 2017-09-30 WO PCT/US2017/054668 patent/WO2018067422A1/en not_active Ceased
- 2017-09-30 HR HRP20211965TT patent/HRP20211965T1/hr unknown
- 2017-09-30 CN CN202110514751.5A patent/CN113214278B/zh active Active
- 2017-09-30 MX MX2019003649A patent/MX390005B/es unknown
- 2017-09-30 ES ES17858944T patent/ES2901216T3/es active Active
- 2017-09-30 PT PT178589446T patent/PT3509591T/pt unknown
- 2017-09-30 PL PL17858944T patent/PL3509591T3/pl unknown
- 2017-09-30 US US17/526,799 patent/USRE49834E1/en active Active
- 2017-09-30 RS RS20211521A patent/RS62695B1/sr unknown
- 2017-09-30 DK DK17858944.6T patent/DK3509591T3/da active
- 2017-09-30 KR KR1020197009016A patent/KR102399848B1/ko active Active
- 2017-09-30 NZ NZ751284A patent/NZ751284A/en unknown
- 2017-09-30 EP EP17858944.6A patent/EP3509591B1/en active Active
- 2017-09-30 EA EA201990523A patent/EA201990523A1/ru unknown
-
2019
- 2019-03-13 IL IL265358A patent/IL265358B/en unknown
-
2022
- 2022-02-17 AU AU2022201058A patent/AU2022201058B2/en active Active
- 2022-02-17 AU AU2022201061A patent/AU2022201061B2/en active Active
- 2022-03-10 IL IL291265A patent/IL291265B2/en unknown
- 2022-03-10 IL IL291267A patent/IL291267B2/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014071031A1 (en) * | 2012-11-01 | 2014-05-08 | Incyte Corporation | Tricyclic fused thiophene derivatives as jak inhibitors |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108366994B (zh) | 新型Jak1选择性抑制剂及其用途 | |
| JP5629324B2 (ja) | ピロロ［２，３−ｄ］ピリミジン化合物 | |
| KR102336291B1 (ko) | 암을 치료하기 위한 ＮＩＫ 억제제로서의 3-(2-아미노피리미딘-4-일)-5-(3-하이드록시프로피닐)-1Ｈ-피롤로[2,3-ｃ]피리딘 유도체 | |
| TWI406864B (zh) | 化合物 | |
| CN120535512A (zh) | Rip1抑制性化合物以及制备和使用其的方法 | |
| TW202304880A (zh) | Ｎ２－苯基嘧啶－２，４－二胺化合物及其製備方法及使用方法 | |
| AU2016301212A1 (en) | Inhibitors of ACK1/TNK2 tyrosine kinase | |
| TW202214603A (zh) | 一種噠嗪類衍生物游離鹼晶型及其製備方法和應用 | |
| WO2019070167A1 (ru) | Ингибиторы рецептора эпидермального фактора роста | |
| WO2019057112A1 (zh) | 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用 | |
| CN113214230B (zh) | 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用 | |
| HK40047523A (en) | Novel jak1 selective inhibitors and uses thereof | |
| HK40047523B (en) | Novel jak1 selective inhibitors and uses thereof | |
| CA3039178C (en) | Novel jak1 selective inhibitors and uses thereof | |
| HK40004735B (en) | Novel jak1 selective inhibitors and uses thereof | |
| BR112019005969B1 (pt) | Inibidores seletivos de jak1 e usos dos mesmos | |
| EA040948B1 (ru) | Селективные ингибиторы jak1 и их применение | |
| HK40079587B (zh) | 一种哒嗪类衍生物自由碱的晶型及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20180808 Address after: 510663 room 205, B tower, poly Central Plaza, 105 Pao Yue Road, Whampoa District, Guangzhou, Guangdong. Applicant after: Guangzhou Gao Ling Pharmaceutical Co.,Ltd. Address before: American Florida Applicant before: Liang Congxin |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1253040 Country of ref document: HK |
|
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: Room 301, 302, building 4, Hexiang science and technology center, Qiantang new area, Hangzhou, Zhejiang Province 310000 Applicant after: Hangzhou Gaoguang Pharmaceutical Co.,Ltd. Address before: Room 1-901, Heda Yaogu center, 291 Fucheng Road, Xiasha street, Qiantang New District, Hangzhou, Zhejiang Province Applicant before: Hangzhou Gaoling Pharmaceutical Co.,Ltd. Address after: Room 1-901, Heda Yaogu center, 291 Fucheng Road, Xiasha street, Qiantang New District, Hangzhou, Zhejiang Province Applicant after: Hangzhou Gaoling Pharmaceutical Co.,Ltd. Address before: Room 205, B / F, poly Zhongke Plaza, No. 105, guanyue Road, Huangpu District, Guangzhou City, Guangdong Province 510663 Applicant before: Guangzhou Gao Ling Pharmaceutical Co.,Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1253040 Country of ref document: HK |